Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fusion Pharmaceuticals Q4 2023 GAAP EPS $(0.39) Misses $(0.34) Estimate

Author: Benzinga Newsdesk | March 20, 2024 04:22pm
Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.34) by 14.71 percent.

Posted In: FUSN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist